Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Jorge A. Garcia, MD, elaborates on the role of PARP inhibitors in the treatment of mCRPC

Dr. Garcia, Division Chief of Solid Tumor Oncology, George & Edith Richman Distinguished Scientist Chair, University Hospitals Seidman Cancer Center, elaborates on the role of PARP inhibitors in the treatment of metastatic castration-resistant prostate cancer (mCRPC)

Tags: ASCO GU Conference CoverageProstate

Published: 23 February 2021

Recent Videos: ASCO GU Conference Coverage

video

Eleni Efstathiou, MD, PhD, regarding the PROSPER clinical trial from ASCO GU 2021

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Eleni Efstathiou, MD, PhD, offers opinion on the ACIS clinical trial

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Eleni Efstathiou, MD, PhD, elaborates on the role of chemotherapy in mCRPC

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Eleni Efstathiou, MD, PhD, discusses the prostate-specific membrane antigen (PSMA) lutetium

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Eleni Efstathiou, MD, PhD, considers the role of precision medicine in prostate cancer

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Eleni Efstathiou, MD, PhD, regarding the preliminary analysis of belzutifan & cabozantinib in ccRCC

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Eleni Efstathiou, MD, PhD, offers a message for patients on clinical progress in prostate cancer

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Matthew Galsky, MD, shares a message for patients regarding clinical progress in bladder cancer

Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, ...

video

Matthew Galsky, MD, on the role of PD-L1 testing in previously untreated, locally advanced or mUC

Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, ...

video

Matthew Galsky, MD, elaborates on outcomes from the CheckMate 274 trial

Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, ...

Related Videos

video-image

Eleni Efstathiou, MD, PhD, regarding the PROSPER clinical trial from ASCO GU 2021

video-image

Eleni Efstathiou, MD, PhD, offers opinion on the ACIS clinical trial

video-image

Eleni Efstathiou, MD, PhD, elaborates on the role of chemotherapy in mCRPC

video-image

Eleni Efstathiou, MD, PhD, discusses the prostate-specific membrane antigen (PSMA) lutetium

video-image

Eleni Efstathiou, MD, PhD, considers the role of precision medicine in prostate cancer

video-image

Eleni Efstathiou, MD, PhD, regarding the preliminary analysis of belzutifan & cabozantinib in ccRCC

video-image

Eleni Efstathiou, MD, PhD, offers a message for patients on clinical progress in prostate cancer

video-image

Matthew Galsky, MD, shares a message for patients regarding clinical progress in bladder cancer

video-image

Matthew Galsky, MD, on the role of PD-L1 testing in previously untreated, locally advanced or mUC

video-image

Matthew Galsky, MD, elaborates on outcomes from the CheckMate 274 trial

video-image

Matthew Galsky, MD, regarding Cohort 2 of the EV-201 trial presented at ASCO GU 2021

video-image

Matthew Galsky, MD, tells us about the design and outcomes of the EV-301 trial from ASCO GU '21

video-image

Jorge A. Garcia, MD, summarizes the significance of CheckMate 9ER from ASCO GU 2021

video-image

Jorge A. Garcia, MD, on the real-world analysis of abiraterone acetate & docetaxel in mHSPC

video-image

Jorge A. Garcia, MD, offers opinion on the role of chemotherapy in the treatment of mCRPC

video-image

Jorge A. Garcia, MD, discusses highlights from the final analysis of the TITAN study

video-image

Sumanta K. Pal, MD, offers a message to patients regarding clinical progress in kidney cancer

video-image

Sumanta K. Pal, MD, shares thoughts on the TIVO-3 trial from ASCO GU 2021

video-image

Sumanta K. Pal, MD, offers opinion on the treatment of clear cell renal cell carcinoma

video-image

William K. Oh, MD, considers the role of PARP inhibitors in mCRPC

video-image

Sumanta K. Pal, MD, elaborates on the significance of the CLEAR trial from ASCO GU 2021

video-image

William K. Oh, MD, summarizes outcomes from the ACIS study as presented at ASCO GU 2021

video-image

Sumanta K. Pal, MD, regarding the quality of life outcomes from CheckMate 9ER

video-image

William K. Oh, MD, offers opinion on the final analysis of the TITAN study

video-image

Sumanta K. Pal, MD, considers the unmet needs in the treatment of papillary RCC

video-image

William K. Oh, MD, offers opinion on the role of chemotherapy in the treatment of mCRPC

video-image

Sumanta K. Pal, MD, elaborates on the design and outcomes of the PAPMET trial from ASCO GU 2021

video-image

William K. Oh, MD, on the real-world analysis of abiraterone & docetaxel in mHSPC

video-image

Robert J. Motzer, MD, elaborates on key findings from the Phase III CLEAR trial

video-image

Robert J. Motzer, MD, offers opinion on whether findings from the CLEAR trial are practice-changing

video-image

Robert J. Motzer, MD, discusses the side effect profiles of the combinations in the CLEAR trial

video-image

Robert J. Motzer, MD, speculates on the future role of combination therapy in advanced ccRCC

video-image

Robert J. Motzer, MD, considers the issue of drug resistance in treating advanced ccRCC

video-image

David A. Braun, MD, PhD, regarding the follow-up trial investigating MK-6482 in ccRCC

video-image

Jeanny B. Aragon-Ching, MD, FACP, offers opinion on the role of chemotherapy in mCRPC

video-image

David A. Braun, MD, PhD, discusses the preliminary analysis of belzutifan + cabozantinib in ccRCC

video-image

Jeanny B. Aragon-Ching, MD, FACP, elaborates on the IMvigor130 trial

video-image

Jeanny B. Aragon-Ching, MD, FACP, provides perspective on CheckMate-274

video-image

Jeanny B. Aragon-Ching, MD, FACP, elaborates on the EV-201 clinical trial

video-image

Jeanny B. Aragon-Ching, MD, FACP, shares the design and outcomes of the EV-301 clinical trial

video-image

Jeanny B. Aragon-Ching, MD, FACP, regarding the CheckMate-9ER trial presented at GU 2021

video-image

Tanya Dorff, MD, on how checkpoint inhibitors are being incorporated into mCRPC treatment algorithms

video-image

Daniel M. Geynisman, MD, on how real-world analysis influences clinical decision-making

video-image

Tanya Dorff, MD, regarding the role of CAR-T cell therapy in the management of PSCA+ mCRPC

video-image

Elisabeth Heath, MD, FACP, explains the design and outcomes of the ACIS study from ASCO GU 2021

video-image

Daniel M. Geynisman, MD, on the real-world analysis of abiraterone acetate & docetaxel in mHSPC

video-image

Tanya Dorff, MD, on the role of chemotherapy in mCRPC patients who have failed prior therapies

video-image

Elisabeth Heath, MD, FACP, provides opinion on PSA screening in prostate cancer

video-image

Daniel M. Geynisman, MD, considers implications for patients as a result of the RETAIN BLADDER trial

video-image

Tanya Dorff, MD, explains the design and outcomes of the ACIS clinical trial

video-image

Elisabeth Heath, MD, FACP, offers perspective on the KEYNOTE-365 clinical study

video-image

Daniel M. Geynisman, MD, explains the risk-adapted approach used in the RETAIN BLADDER trial

video-image

Tanya Dorff, MD, offers impressions of the updated TITAN clinical trial from ASCO GU 2021

video-image

Elisabeth Heath, MD, FACP, shares updated results of the TITAN clinical trial from ASCO GU 2021

video-image

Daniel M. Geynisman, MD, provides an overview of the RETAIN BLADDER presented at ASCO GU 2021

video-image

Thomas Powles, MD, PhD, FCRP, offers opinion on whether the results of EV-301 are practice-changing

video-image

Thomas Powles, MD, PhD, FCRP, regarding the EV-301 Phase III clinical study from ASCO GU 2021

video-image

Kim N. Chi, MD, speculates on the future role of apalutamide in the treatment of prostate cancer

video-image

Thomas Powles, MD, PhD, FCRP, tell us about the novel antibody-drug conjugate enfortumab vedotin

video-image

Kim N. Chi, MD, outlines the safety profile of apalutamide

video-image

Thomas Powles, MD, PhD, FCRP, on the impact of I-O in the management of metastatic UC

video-image

Kim N. Chi, MD, on what findings from the Phase III TITAN study mean for patients

video-image

Arlene Siefker-Radtke, MD, regarding the EV-201 Cohort 2 study & clinical implications for patients

video-image

Kim N. Chi, MD, considers the impact of the crossover design in the analysis of the TITAN study

video-image

Arlene Siefker-Radtke, MD, discusses key takeaways from the EV-301 study in urothelial cancer

video-image

Kim N. Chi, MD, regarding key highlights from the final analysis of the Phase III TITAN study

video-image

Arlene Siefker-Radtke, MD, on the management of treatment-emergent AEs & the use of FGFR inhibitors

video-image

David Braun, MD, PhD, shares how the treatment of ccRCC in the refractory setting is changing

video-image

Arlene Siefker-Radtke, MD, discusses some of the antibody drug conjugates currently in development

video-image

David Braun, MD, PhD, considers the evolving treatment landscape of 1st line ccRCC

video-image

Arlene Siefker-Radtke, MD, speculates on the role of antibody drug conjugates in the treatment of UC

video-image

David Braun, MD, PhD, offers opinion on the role of HIF-2α inhibitors in ccRCC

video-image

Eleni Efstathiou, MD, PhD, provides perspective on the IPATential150 study in mCRPC

video-image

Eleni Efstathiou, MD, PhD, on whether genetic mutation data impacts the treatment of prostate cancer

video-image

Eleni Efstathiou, MD, PhD, on the practice-changing potential of the PROfound study from ESMO 2020

video-image

Matthew Galsky, MD, on how studies focused on genetic mutations impact prostate cancer treatment

video-image

Arun Azad, MBBS, PhD, FRACP, on the evolving treatment landscape of advanced prostate cancer

video-image

Matthew Galsky, MD, discusses the practice-changing potential of the PROfound study from ESMO 2020

video-image

Arun Azad, MBBS, PhD, FRACP, considers how recent clinical trials influence the treatment of mCRPC

video-image

Arun Azad, MBBS, PhD, FRACP, tells us about the outcomes of the PROfound study presented at ESMO '20

video-image

Arun Azad, MBBS, PhD, FRACP, shares impressions of the post-hoc analysis of the ARCHES study

video-image

Nicholas James, MD, PhD, offers a summary of the STAMPEDE study to date

video-image

Nicholas James, MD, PhD, analyzes the duration of response in Arm G of the STAMPEDE clinical trial

video-image

Petros Grivas, MD, PhD, summarizes the clinical progress made in prostate cancer from ESMO 2020

video-image

Maha Hussain, MD, provides perspective on the Phase III PROfound study presented at ESMO 2020

video-image

Maha Hussain, MD, shares the design of the Phase III PROfound study in mCRPC

video-image

Maha Hussain, MD, considers the role of homologous recombination repair in the management of mCRPC

video-image

Maha Hussain, MD, regarding the evolving treatment landscape of mCRPC

video-image

Rana McKay, MD, shares results of the randomized Phase 2 study investigating luPSMA vs cabazitaxel

video-image

Rana McKay, MD, elaborates on the advent of hormonal agents for patients with metastatic prostate cancer

video-image

Derek Raghavan, MD, discusses the efficacy and utility of the new GNRH antagonist, Reugolix

video-image

Derek Raghavan, MD, explains toxicities and factors determining GNRH-based therapies selection

video-image

Derek Raghavan, MD, provides a general overview of prostate cancer therapies

video-image

Nicholas Vogelzang, MD, FASCO, FACP, describes the role of PARP inhibitors advanced prostate cancer

video-image

Nicholas Vogelzang, MD, FASCO, FACP, provides updates on PSMA radioligands for PET imaging

video-image

Nicholas Vogelzang, MD, discusses re-emergence of dose reduced cabozantinib + alezotuzumab in advanced prostate cancer

video-image

Nicholas Vogelzang, MD, provides thoughts on the role of radium 223 in management of advanced metastatic prostate cancer

video-image

Nicholas Vogelzang, MD, explains how cabazitaxel should be used in various lines of treatment in metastatic prostate cancer

video-image

Nicholas Vogelzang, MD, FASCO, FACP, considers the dosing effects of cabazitaxel in clinical studies

video-image

Nicholas Vogelzang, MD, FASCO, FACP, on CARD study impressions comparing novel hormonal therapy to cabazitaxel

video-image

Nicholas Vogelzang, MD, FASCO, FACP, updates us on the status of PSMA-linked radiopharmaceuticals

video-image

Tomasz Beer, MD, FACP, discusses the recently FDA approved relugolix

video-image

Tomasz Beer, MD, FACP, provides preliminary data presented concerning androgen receptor degraders

video-image

Tomasz Beer, MD, FACP, on how to treat patients who are progressing on androgen receptor inhibitors

video-image

Tomasz Beer, MD, FACP, explains which nmCRPC patients to treat with androgen receptor inhibitors

video-image

Tomasz Beer, MD, FACP, reviews updates concerning androgen receptor inhibitors in nmCRPC

video-image

Scott Tagawa, MD, elaborates on what may account for resistance to PSMA radioligand therapies

video-image

Scott Tagawa, MD, explains how PSMA PET imaging is utilized with PSMA-based therapies

video-image

Scott Tagawa, MD, defines the 177Lutethium Beta emitter and the 225Actinium Alpha emitter PMSA-linked therapies

video-image

Scott Tagawa, MD, considers next steps in the development of the PSMA-targeted alpha emitter in mCRPC

video-image

Scott Tagawa, MD, discusses the results of Phase I dose-escalation study regarding mCRPC

video-image

Fred Saad MD, on SPARTAN study highlights for oncologists that do not specialize in prostate cancer

video-image

Fred Saad, MD, on genetic testing to be conducted in a patient with metastatic prostate cancer

video-image

Fred Saad, MD, shares impressions of the CARD study investigating cabazitaxel in nmCRPC patients

video-image

Fred Saad, MD, details safety concerns when prescribing apalutamide + ADT to nmCRPC patients

video-image

Fred Saad, MD, shares the design and outcomes of the SPARTAN study in patients with nmCRPC